RNMT is a promising therapeutic target in PIK3CA (phosphatidylinositol-4,5- bisphosphate 3-kinase catalytic subunit alpha gene) mutant breast cancer, as PIK3CA mutations in breast cells depend on RNMT (mRNA cap methylation) for their survival and proliferation13. This evidence concerns the gene RNMT and breast carcinoma.